Abstract A major challenge in advancing neoantigen-targeted therapies lies in the limited capacity of predicted neoantigens to robustly activate CD8+ T cells, emphasizing the critical need for comprehensive functional validation before patient vaccination. Here, we provide a direct comparison of neoantigen-specific T cell responses between vaccinated patients with cancer and HLA-matched healthy donors.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Get in touch with Shuting
Contact Shuting, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack